Status:
UNKNOWN
Chromatic Pupillometry to Assess the Melanopsin-Light Pathway in Progressive Supranuclear Palsy
Lead Sponsor:
Massachusetts General Hospital
Collaborating Sponsors:
NeurOptics Inc.
University of Toronto
Conditions:
PSP - Progressive Supranuclear Palsy
PD - Parkinson's Disease
Eligibility:
All Genders
55+ years
Brief Summary
The specific aim of this study is to investigate rod, cone and melanopsin driven pupillary light response in individuals with progressive supranuclear palsy (PSP), age-matched healthy controls and ind...
Detailed Description
In 1963, Richardson, Steele and Olszewski published a landmark clinical report on 8 cases of supranuclear ophthalmoplegia, pseudobulbar palsy, nuchal dystonia and dementia and established the syndrome...
Eligibility Criteria
Inclusion
- Individuals that meet the clinical criteria for PSP. Core features include:
- Recurrent falls and unsteady gait
- Axial and nuchal rigidity
- Pseudobulbar palsy
- Bilateral lid retraction
- Supranuclear vertical gaze palsy
- Atrophy of the midbrain tegmentum (the hummingbird sign on brain MRI,
- Individuals that fit the criteria for the second PSP phenotype (which resembles PD) that has asymmetric findings, tremors and poor responses to treatment with Levodopa,
- Individuals that meet the clinical criteria for PD with:
- Progressive bradykinesia
- Postural instability and frequent falls
- Festinating gait with loss of associated movements
- Cogwheel rigidity and mask-like face
- Rest tremor,
- Individuals who carry a diagnosis of Alzheimer' disease who present with progressive impairment of memory and cognitive domains such as language and visuospatial perception.
- Diagnoses will be confirmed by the review of health/medical records of patients recruited from the Frontotemporal Disorders Unit clinic. In the case of participants recruited from research studies, diagnoses will be confirmed by the review of the research diagnoses indicated on the individuals' research records.
Exclusion
- Individuals who are frail or in questionable health,
- Individuals with cataracts or with posterior pole ocular pathology such as age-related macular degeneration and optic neuropathies, including open angle high intraocular pressure glaucoma,
- Individuals with photophobia (i.e., painful light sensitivity) when exposed to bright light, including those with ophthalmological conditions such as keratitis (herpes simplex), uveitis or Achromatopsia,
- Individuals with advanced dementia with inability to sit erect, hold the eyes open, incontinence,
- Individuals with epilepsy,
- Individuals diagnosed with major depression or other severe psychiatric disorders
Key Trial Info
Start Date :
November 1 2017
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
October 1 2019
Estimated Enrollment :
56 Patients enrolled
Trial Details
Trial ID
NCT03330353
Start Date
November 1 2017
End Date
October 1 2019
Last Update
November 7 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114